trial · primary record
LTI-03
Idiopathic Pulmonary Fibrosis (IPF)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs) |
| Registry ID | NCT06968845 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:43.606Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06968845
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.